Storia in 2 fonti

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 g fa

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

originale

endpoints.news2 g fa

After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug

Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's Hansoh Pharmaceutical for $120 million upfront.

Leggi questa versione → originale

Timeline cronologica

martedì 14 luglio 2026·biopharmadive.com
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
martedì 14 luglio 2026·endpoints.news
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug
Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's Hansoh Pharmaceutical for $120 million upfront.